HBIO harvardbioscience.com Expected Profit

Global production diversification minimizes geopolitical risks for Harvard Bioscience (HBIO). The estimated profit metric visualizes these trends, and the current value of the indicator is 0.00. The supply of laboratory systems and dosing pumps ensures stability. A high level of capital transparency and the experience of top management guarantee investors the protection of their interests and the competent management of the company's resources.

HBIO - Harvard Bioscience Inc. Expected Net Income over the range 07/04/2022 - 11/11/2026

Analytical breakdowns for harvardbioscience.com (HBIO)

- share price and consensus valuation forecast:

Stock Price Harvard Bioscience Inc.|HBIO - Analyst Consensus Forecast

- market capitalization data:

Market Value Harvard Bioscience Inc.|HBIO - Total Company Value

- company book value details:

Accounting Value per Share Harvard Bioscience|HBIO - Accounting Value of Company|Market Capitalization to Book Value Ratio harvardbioscience.com|HBIO - Company Total Asset Base

- debt and solvency information:

- earnings and market ratios statistics:

HBIO - Net Profit|Expected Profit Harvard Bioscience|HBIO - Price to Earnings Ratio|Forward P/E Multiple Harvard Bioscience Inc.|HBIO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harvard Bioscience, Inc.|HBIO - Operating profit before amortization|Net earnings per share for the last 12 months Harvard Bioscience|HBIO - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months harvardbioscience.com|HBIO - Expected net earnings per share growth this year|Earnings growth forecast for next year Harvard Bioscience

- sales and revenue indicators:

HBIO - Company Sales Revenue|Projected Sales Volume harvardbioscience.com|HBIO - P/S Multiple|Price-to-Projected Revenue Ratio Harvard Bioscience

Initial company analysis:Harvard Bioscience, Inc.

This indicator represents an aggregated assessment of future earnings per share, adjusted for short-term market volatility. This metric measures the long-term profitability vector, balancing growth potential with financial stability. For Harvard Bioscience (HBIO), this forecast depends directly on the stability of scientific research grants and the absence of technological substitution. By analyzing the trend of the company's projected revenues, an investor can assess the risks of profit shortfalls resulting from reductions in university budgets.

Direct competitors